KGK Science and Nova Mentis Life Science will carry out a Phase 2a clinical trial testing the efficacy of psilocybin microdosing on Fragile X Syndrome.
Sintalica Bioscience has received, through the University of Messina, authorisations from the Italian Ministry of Health pertaining to its drug development programme.
Clarify Pharma has acquired shares to the value of £250,000 in each of Atai Life Sciences and Compass Pathways as part of its investment strategy.
Clearmind Medicine will be embarking on a first-in-human clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).
Awakn Life Sciences has announced the signing of a five-year lease to open a larger Awakn Clinics Oslo.
Mindset Pharma and PharmaAla have entered into an exclusive sales agreement for the sale and distribution of pharmaceutical-grade psilocybin.
Canadian pharmaceutical development company Algernon Pharmaceuticals has commenced screening subjects for its Phase 1 clinical study of an intravenous formulation of DMT – AP-188 – in...
Canadian non-profit TheraPsil has announced that patients and medical professionals from across Canada will be reaching out to Parliamentarians to raise awareness of the medical benefits...
A team at the Allen Institute for Brain Science, a division of the Allen Institute, has sent brain samples on a “trip” to gain insights into...
Beckley Psytech has announced the successful completion of its Phase I clinical study of lead candidate BPL-003, a novel benzoate formulation of 5-MeO-DMT.